摘要
目的:探讨正电子发射型断层扫描技术(PET)融合计算机断层扫描(CT)即PET/CT显像在淋巴瘤诊断、分期及疗效评价中的价值。方法:对14例经病理学确诊的淋巴瘤患者行PET/CT显像,显像剂18F-脱氧葡萄糖(18F-FDG)用量10-14mCi(370-518MBq),并与同期CT、MRI或B超等影像检查结果(CI)进行对比分析,随访时间6个月以上。结果:14例PET/CT显像阳性13例(92.8%)。3例(21.4%)为淋巴瘤初诊治疗前检查,PET/CT显像均阳性,PET标准摄取值(SUV,正常<2.5)分别为3.7、3.5和11.4;11例(78.5%)淋巴瘤治疗2-4疗程后行PET/CT显像,11例中3例(21.4%)肿块全部处于高代谢状态,临床确认有肿瘤明显残余或复发,SUV分别为11.7、10.1和5.7,8例(57.1%)临床疗效为完全缓解(CR)和部分缓解(PR)的患者中,PET/CT显像阳性7例并示肿块处于抑制状态,其中2例SUV升高分别为3.6和2.8,但术后病理证实为假阳性。共有3例(21.4%)淋巴瘤PET/CT显像新发现恶性病灶而提高临床分期,改变了进一步临床治疗方案。结论:18F-FDGPET/CT显像能灵敏、准确地检出淋巴瘤病灶特别是复发及残余病灶,对淋巴瘤诊断、分期、疗效评价及指导临床治疗有重要价值。
Objective：To investigate the clinical value of 18F - fluorodeoxyglucose （FDG） PET/CT imaging for the diagnosis , staging and treatment evaluation of lymphoma. Methods：IS F - FDG PET/CT imaging was performed on 14 pathologically proved lymphoma patients and the results were compared with those of other conventional imaging （CI） modalities including CT, MRI or ultrasound. All patients were followed up over 6 months. Results：IS F - FDG PET/CT imaging was positive in 13 of the 14 cases with lymphoma （92.8 % ）. Positive PET/CT imaging was performed on three patients before treatment, and the maximum standardized uptake values （SUV） were 3.7, 3.5 and 11.4, respectively. PET/CT imaging was performed on the other 11 patients after 2 -4 courses of treatment, among them PET/CT imaging was still positive in 3 cases with recurrent or remnant tumor, which indicates that the tumors were active ; the SUV were 11.7, 10.1 and 3.5, respectively. In 8 cases with complete or partial remission, 7of the 8 PET/CT imaging cases were positive and the tumors were mildly suppressed;2cases were positive and the SUV were 3.6 and 2.8, respectively, but they were false positive after review of pathology. 18F - FDG PET/CT imaging upstaged in 21.4% （3/14） of the lymphoma patients, therefore PET/CT imaging changed the therapeutic regimen. Condusion：PET/CT imaging is an effective and accurate method and it can delineate the tumor distribution of lymphoma, especially those of the recurrent or remnant tumor. It is of significant value for the diagnosis, staging, treatment evaluation and therapeutic guidance of lymphoma.
出处
《现代肿瘤医学》
CAS
2008年第8期1396-1398,共3页
Journal of Modern Oncology
